Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment
PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment
7
Participants
Timeline
Start Date
April 30, 2015
Primary Completion Date
June 30, 2020
Study Completion Date
September 20, 2020
Conditions
Advanced Gastric Adenocarcinoma
Interventions
DRUG
AZD6094
DRUG
docetaxel
Trial Locations (1)
135-710
Samsung Medical Center, Seoul
All Listed Sponsors
lead
Samsung Medical Center
OTHER
NCT02447406 - Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment | Biotech Hunter | Biotech Hunter